HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Shareholders Push For More Power Over Board Membership

This article was originally published in The Tan Sheet

Executive Summary

With more power to shake up P&G’s board, shareholders could ultimately have a greater hand in changes to company management. Activist investor William Ackman – whose firm Pershing Square Capital owns roughly a 1% stake in the firm – is rumored to be pushing to replace P&G CEO Bob McDonald.

You may also be interested in...



P&G Defends Savings/Growth Strategy, Plans To Slash More Prices In FY 2013

P&G will roll back about $400 million of the $3.5 billion in pricing increases taken in fiscal year 2012, in an effort to include beauty and health-care products. Beauty sales declined 4% on the year, the firm reported.

Activist Investor May Push P&G To Sell Non-Core Brands, Oust CEO McDonald

Changes may be ahead for Procter & Gamble following William Ackman and Pershing Square Capital Management’s investment in the consumer products giant. Analysts suggest the activist investor may push to replace CEO Bob McDonald and divest non-core brands.

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS125090

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel